Limits...
Hepatitis B virus seroprevalence and its correlation with CD4 cells and liver enzymes among human immunodeficiency virus positive individuals at a tertiary care hospital in North-West India.

Hooja S, Singhal A, Bachhiwal R, Yadav R, Vyas N - Int J Appl Basic Med Res (2015 Jan-Apr)

Bottom Line: Categorical data revealed significantly higher proportion of alanine aminotransferase and aspartate aminotransferase (AST) in the co-infected patients compared to the monoinfected patients (P < 0.05).The HIV/HBV co-infected patients had significantly lower CD4 T-cell counts (P = 0.03) and significantly higher AST, alkaline phosphatase and serum bilirubin values (P = 0.023, P = 0.029, P = 0.009 respectively) than the monoinfected group.These findings underscore the importance of HBV screening of all HIV positive individuals before initiating antiretroviral treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, SMS Medical College, Jaipur, Rajasthan, India.

ABSTRACT

Background: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are global health concerns. Due to shared routes of transmission, co-infection is common. Their co-existence can cause severe liver complications and immunological impairment in infected individuals.

Aim: To find the prevalence of HBV co-infection in HIV patients and to assess the pattern of liver enzymes and CD4 T-cell counts in HIV monoinfected and HIV/HBV co-infected patients.

Materials and methods: A total of 342 consecutive confirmed HIV positive treatment naïve patients were tested for hepatitis B surface antigen (HBsAg). Clinical staging was done according to Centers for Disease Control and Prevention classification guidelines. Liver function tests were performed by an autoanalyser. CD4 T-cells were estimated by FACS Calibur.

Results: Hepatitis B virus co-infection was detected in 8.7% of HIV positive patients as compared to 1.42% in the HIV negative control group (P < 0.05). Majority of the HIV monoinfected and co-infected patients were below 38 years. HBsAg positivity was higher in males (9.4%) and the route of transmission was heterosexual. Categorical data revealed significantly higher proportion of alanine aminotransferase and aspartate aminotransferase (AST) in the co-infected patients compared to the monoinfected patients (P < 0.05). The HIV/HBV co-infected patients had significantly lower CD4 T-cell counts (P = 0.03) and significantly higher AST, alkaline phosphatase and serum bilirubin values (P = 0.023, P = 0.029, P = 0.009 respectively) than the monoinfected group. Males had 1.33 times higher risk than females for co-infection (odds ratio = 1.33; 95% confidence interval 0.57-3.10).

Conclusion: The prevalence of co-infection was high. Raised levels of liver enzymes and lowered CD4 counts were seen in co-infected patients. These findings underscore the importance of HBV screening of all HIV positive individuals before initiating antiretroviral treatment.

No MeSH data available.


Related in: MedlinePlus

Categorical data of aspartate aminotransferase and alanine aminotransferase in human immunodeficiency virus (HIV) monoinfected and HIV/hepatitis B virus co-infected patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318099&req=5

Figure 2: Categorical data of aspartate aminotransferase and alanine aminotransferase in human immunodeficiency virus (HIV) monoinfected and HIV/hepatitis B virus co-infected patients

Mentions: The mean ALT, AST and ALP levels in HIV monoinfected patients were 37 U/L, 59 U/L and 236 IU/L respectively. The mean ALT, AST and ALP levels in HIV/HBV co-infected patients were 49 U/L, 78 U/L and 874 IU/L respectively. The baseline values are shown in Table 2. Co-infected patients had higher proportions of elevated values of AST (86.6% vs. 51.6%) and ALT (56.6% vs. 25.3%) than HIV alone [Figure 2]. The difference was statistically significant (P < 0.05).


Hepatitis B virus seroprevalence and its correlation with CD4 cells and liver enzymes among human immunodeficiency virus positive individuals at a tertiary care hospital in North-West India.

Hooja S, Singhal A, Bachhiwal R, Yadav R, Vyas N - Int J Appl Basic Med Res (2015 Jan-Apr)

Categorical data of aspartate aminotransferase and alanine aminotransferase in human immunodeficiency virus (HIV) monoinfected and HIV/hepatitis B virus co-infected patients
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318099&req=5

Figure 2: Categorical data of aspartate aminotransferase and alanine aminotransferase in human immunodeficiency virus (HIV) monoinfected and HIV/hepatitis B virus co-infected patients
Mentions: The mean ALT, AST and ALP levels in HIV monoinfected patients were 37 U/L, 59 U/L and 236 IU/L respectively. The mean ALT, AST and ALP levels in HIV/HBV co-infected patients were 49 U/L, 78 U/L and 874 IU/L respectively. The baseline values are shown in Table 2. Co-infected patients had higher proportions of elevated values of AST (86.6% vs. 51.6%) and ALT (56.6% vs. 25.3%) than HIV alone [Figure 2]. The difference was statistically significant (P < 0.05).

Bottom Line: Categorical data revealed significantly higher proportion of alanine aminotransferase and aspartate aminotransferase (AST) in the co-infected patients compared to the monoinfected patients (P < 0.05).The HIV/HBV co-infected patients had significantly lower CD4 T-cell counts (P = 0.03) and significantly higher AST, alkaline phosphatase and serum bilirubin values (P = 0.023, P = 0.029, P = 0.009 respectively) than the monoinfected group.These findings underscore the importance of HBV screening of all HIV positive individuals before initiating antiretroviral treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, SMS Medical College, Jaipur, Rajasthan, India.

ABSTRACT

Background: Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are global health concerns. Due to shared routes of transmission, co-infection is common. Their co-existence can cause severe liver complications and immunological impairment in infected individuals.

Aim: To find the prevalence of HBV co-infection in HIV patients and to assess the pattern of liver enzymes and CD4 T-cell counts in HIV monoinfected and HIV/HBV co-infected patients.

Materials and methods: A total of 342 consecutive confirmed HIV positive treatment naïve patients were tested for hepatitis B surface antigen (HBsAg). Clinical staging was done according to Centers for Disease Control and Prevention classification guidelines. Liver function tests were performed by an autoanalyser. CD4 T-cells were estimated by FACS Calibur.

Results: Hepatitis B virus co-infection was detected in 8.7% of HIV positive patients as compared to 1.42% in the HIV negative control group (P < 0.05). Majority of the HIV monoinfected and co-infected patients were below 38 years. HBsAg positivity was higher in males (9.4%) and the route of transmission was heterosexual. Categorical data revealed significantly higher proportion of alanine aminotransferase and aspartate aminotransferase (AST) in the co-infected patients compared to the monoinfected patients (P < 0.05). The HIV/HBV co-infected patients had significantly lower CD4 T-cell counts (P = 0.03) and significantly higher AST, alkaline phosphatase and serum bilirubin values (P = 0.023, P = 0.029, P = 0.009 respectively) than the monoinfected group. Males had 1.33 times higher risk than females for co-infection (odds ratio = 1.33; 95% confidence interval 0.57-3.10).

Conclusion: The prevalence of co-infection was high. Raised levels of liver enzymes and lowered CD4 counts were seen in co-infected patients. These findings underscore the importance of HBV screening of all HIV positive individuals before initiating antiretroviral treatment.

No MeSH data available.


Related in: MedlinePlus